ProPhase Labs Reports Financial Results for the Fourth

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ProPhase Labs Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015

DOYLESTOWN, PA --(Marketwired - March 29, 2016) - ProPhase Labs, Inc.  ( NASDAQ : PRPH ) ( www.ProPhaseLabs.com ) today reported its net sales were $8.2 million for the three months ended December 31, 2015, as compared to net sales of $9.0 for the three months ended December 31, 2014. The Company incurred a net loss for the three months ended December 31, 2015 of $1.3 million, or ($0.07) per share, compared to a net loss of $676,000, or ($0.05) per share, for the three months ended December 31, 2014. 

The Company's sales are principally derived from its over-the-counter ("OTC") health care and cold remedy products. As a consequence, a significant portion of our business is highly seasonal, which causes significant variations in operating results from quarter to quarter. 

Results for the fourth quarter of 2015 compared to the fourth quarter of 2014 principally reflect the net effect of (i) a decrease in net sales of $809,000 due to a decrease in shipments, (ii) an increase in administration costs of $237,000 due principally to an increase in professional and legal costs and (iii) a decrease in sales and marketing expenses of $764,000. 

The Company generated net sales for the year ended December 31, 2015 of $20.6 million, as compared to $22.1 million for the year ended December 31, 2014. The Company incurred a net loss for the year ended December 31, 2015 of $3.6 million, or ($0.22) per share, compared to a net loss of $7.8 million, or ($0.47) per share, for the year ended December 31, 2014.

The financial results for the year ended December 31, 2015 as compared to the year ended December 31, 2014 reflect the net effect of (i) a decrease in net sales of $1.5 million principally due to (a) a decrease in shipments and lower consumer demand as a consequence of several factors including the decrease in the incidence and severity of upper respiratory illness, offset by (b) a $1.0 million increase in contract manufacturing operations, (ii) a decrease in administration costs of $1.2 million due principally to a decrease in professional and legal costs related to certain, now resolved, litigation matters, (iii) a decrease in sales and marketing expenses of $1.3 million as a consequence of a reduction from period to period of the timing and scope of our marketing initiatives, (iv) a decrease in research and development expenditures of $244,000 and (v) a non-recurring impairment charge to operations of $3.6 million during the third quarter of 2014. According to IMS Health (a healthcare industry information provider), key industry statistics reveal that the incidence of upper respiratory illness across the country has been down 12.6% for the period September through December 2015 as compared to the prior year September through December 2014. The category of cough and cold product sales, including our Cold-EEZE ® sales, are highly correlated to the incidence of upper respiratory illness.

Ted Karkus, the CEO of the Company, stated, "Our product development efforts over the past several years have been largely focused on successfully leveraging the Cold-EEZE ® brand. In order to grow our share of the cold remedy category, in February 2016, at the Efficient Collaborative Retail Marketing ("ECRM") industry trade conference and other related meetings, we met with approximately 80 important retailers and introduced to the trade additional, new and innovative Cold-EEZE ® branded products that will continue to broaden and strengthen our cough/cold product line. Our research and development of new products in the cough/cold category has been robust."

Mr. Karkus continued, "In addition to the continued development and commercialization of new Cold-EEZE ® branded products, we are also preparing to launch a new line of products in the dietary supplement category. In order to offset the seasonality of our current revenues and our dependence on the severity of the cold season, we are launching a new product line of over the counter, dietary supplements that will leverage our existing infrastructure, retail relationships and sales force. Following approximately 2-1/2 years of successful development, we are making our first foray into the dietary supplements category with the launch of our new line of TK Supplements™."

Mr. Karkus added. "Our first new product is Legendz XL™, a men's dietary supplement in the male enhancement category. After extensive research and preparation, we have produced our first set of direct response television spots and begun TV media testing. We have developed an integrated network of strategic vendors including a call center and a fulfillment center as well as the online infrastructure to execute a direct to consumer marketing and sales strategy. Our new Legendz XL™ website is now live: www.LegendzXL.com . We expect to continually refine our consumer engagement, TV spots, TV media plan and websites during the first half of fiscal 2016 and thereafter in order to optimize consumer response and generate product awareness. As with any new product launch, we anticipate losses from the TK Supplements™ initiatives as we optimize our direct response strategy."

Mr. Karkus further stated, "Over time, our goal is for TK Supplements™ results to improve, which will lead to increasing the media spend which will, in turn, broaden brand awareness for our new line of products. As brand awareness increases, our next goal will be to introduce Legendz XL™ in retail stores, leveraging our existing infrastructure and retail distribution platform. We also have developed additional dietary supplements for future introduction at the appropriate time."

Mr. Karkus concluded, "We are committed to executing a long term strategy to grow our Cold-EEZE ® brand and to grow the Company by participating in the large dietary supplement category."

A conference call will be held this morning, March 29 th , at 11:00am EST. ProPhase Labs Chairman and CEO, Ted Karkus, and COO/CFO Robert Cuddihy will provide a company overview including a review of activities and fourth quarter results. There will be a question and answer session following initial remarks.

The conference call will be webcast live at:

  https://engage.vevent.com/rt/prophaselabsincao~032916 at 11:00 AM (EDT) on Tuesday, March 29, 2016.

Participants wishing to ask questions may access the live call by dialing (844) 301-0501 conference ID # 76794886 . A replay of the conference call will be available for 90 days on the company website www.ProPhaseLabs.com .

About ProPhase Labs

ProPhase Labs is a diversified natural health medical science company. It is a leading marketer of the Cold-EEZE ® cold remedy brand as well as other cold and flu relief products. Cold-EEZE ® cold remedy zinc gluconate lozenges are clinically proven to significantly reduce the duration of the common cold. Cold-EEZE ® cold remedy customers include leading national chain, regional, specialty and local retail stores. ProPhase Labs has several wholly owned subsidiaries including a manufacturing unit, which consists of an FDA registered facility to manufacture Cold-EEZE ® cold remedy lozenges and fulfill other contract manufacturing opportunities. For more information visit us at www.ProPhaseLabs.com .

Forward Looking Statements

Except for the historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the launch of our new line of TK Supplements™, and our new product Legendz XL™. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. These risks and uncertainties include, but are not limited to: the difficulty of predicting the acceptance and demand for our products, the impact of competitive products and pricing, costs involved in the manufacture and marketing of products, the timely development and launch of new products, and the risk factors listed from time to time in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any subsequent SEC filings.

 
PROPHASE LABS, INC. & SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
 
  Three Months Ended   Year Ended
    December 31, 2015     December 31, 2014     December 31, 2015     December 31, 2014
    (unaudited)     (unaudited)            
Net sales $ 8,163   $ 8,972   $ 20,604   $ 22,070
                       
Cost of sales   3,375     3,076     8,426     7,891
                       
Gross profit   4,788     5,896     12,178     14,179
                       
Operating expenses:                      
  Sales and marketing   3,476     4,240     7,698     8,965
  Administration   2,152     1,915     6,986     8,143
  Research and development   403     415     1,078     1,322
  Impairment charge   -     -     -     3,577
    6,031     6,570     15,762     22,007
                       
Loss from operations   (1,243)     (674)     (3,584)     (7,828)
                       
Interest income, net   (13)     (2)     (16)     (6)
                       
Loss before income tax   (1,256)     (676)     (3,600)     (7,834)
                       
Income tax   -     -     -     -
                       
Net loss $ (1,256)   $ (676)   $ (3,600)   $ (7,834)
                       
Basic and diluted loss per share:                      
  Net loss $ (0.07)   $ (0.05)   $ (0.22)   $ (0.47)
                       
Weighted average common                      
  shares outstanding:                      
    Basic and diluted   17,081     15,772     16,398     16,773
 
 
PROPHASE LABS, INC. & SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEET DATA
(in thousands)
 
  December 31,   December 31,
  2015   2014
       
  Cash and cash equivalents $ 1,664   $ 2,926
  Accounts receivable, net $ 4,000   $ 5,836
  Inventory $ 4,331   $ 3,292
  Total current assets $ 11,879   $ 13,458
  Total assets $ 14,829   $ 16,057
           
  Total current liabilities $ 4,534   $ 5,241
  Total long term obligations $ 1,466   $ 100
  Total stockholders' equity $ 8,829   $ 10,716

Press Only Contact   Constantine Panagiotatos  DKC Public Relations (212) 981-5124  Constantine_Panagiotatos@dkcnews.com   Investor Contact Ted Karkus Chairman and CEO ProPhase Labs, Inc. (215) 345-0919 x 0

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AMP Tests Debt Market With €1.25 Billion Green Notes

Updated Category News Views 101

Refinancing season has arrived early at Ardagh Metal Packaging, and it is carrying a hefty €1.25 billion price tag. AMP has launched senior secured floating-rate green notes, with proceeds intended to retire two batches of secured debt due in 2028 and leave additional cash on the balance sheet for general corporate purposes, including capital expenditure. This is not...

Continue Reading
Hanon's BMW Thermal Win Matters Beyond the Trophy Case Today

Updated Category News Views 96

A 16-Kilogram Box Just Grabbed the Auto Supply Chain’s Attention Hanon Systems did not win these two 2026 PACE honors by polishing up some old hose-and-valve package. Its Highly Integrated Cooling Entity, or HICE, is aimed right at a stubborn electric-vehicle problem: keeping a vehicle’s thermal systems controlled without turning the architecture into a sprawling,...

Continue Reading
Clarivate's 2026 Research List Carries a Trust Test

Updated Category News Views 183

Seven thousand ninety awards can look like a victory lap until you remember how easily raw citation counts can be gamed. Clarivate’s 2026 Highly Cited Researchers list is more interesting for its insistence on screening than for the familiar names at the top. In a research world where publication volume, self-citation and paper mills have made plenty of people...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 54

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
24X Options Filing Puts Earnings Bets Before the SEC

Updated Category News Views 49

An earnings release already turns the market into a bar fight; 24X wants to put part of that fight inside a regulated binary-options contract. The Stamford-based exchange has filed a proposed rule change with the SEC for 24X Options, a facility that would offer a conventional options market alongside contracts tied to company performance targets. It is an interesting...

Continue Reading
Historic China-Russia-US Summit Aims for Global Stability

Updated Category News Views 85

The Weight of History in Shenzhen When the big players decide to talk face-to-face, it's more than just a photo op. This week in Shenzhen, the leaders of China, Russia, and the United States are doing just that. And let me tell you, it's the kind of gathering that can either stabilize the gears of global politics or grease the wheels of tension. This chinwag isn't just...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 156

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Stitch AI Targets Banking’s Hardest Automation Gap

Updated Category News Views 25

The flashy chatbot stuff is cheap; banking permission to act is not. That is why Stitch AI’s launch deserves more attention than another vendor slapping “agentic” on a slide deck and calling it transformation. Banks do not need a machine to summarize a policy document while everyone applauds the demo. They need technology that can touch real workflows without...

Continue Reading
Caracal’s $200K VMI Pledge Targets Cadet Affordability

Updated Category News Views 217

A tuition award can still leave a brutal hole in the budget. That is the plain fact sitting underneath Caracal Products & Services’ $200,000 commitment to Virginia Military Institute. Federal ROTC scholarships can cover tuition, but VMI says room, board and quartermaster fees average about $15,000 annually. For a student who has done everything right—earned the ROTC...

Continue Reading
A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 131

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading

Top 5 Most Recently Viewed Articles

Voltalia Partners with Retail Giants for EV Charging Stations

Updated Category News Views 165

Innovative Partnership to Enhance Electric Vehicle Charging Voltalia, a prominent name in the renewable energy sector, is making significant strides by collaborating with Auchan, DECATHLON, and Leroy Merlin. This partnership aims to deploy electric vehicle (EV) charging stations across more than 350 parking lots in France, marking a crucial step towards fostering...

Continue Reading
Khanh Phuong Morrow's Strategic Insider Move at Lantheus Holdings

Updated Category News Views 211

Khanh Phuong Morrow's Strategic Insider Decision at Lantheus Holdings In a recent filing, it was disclosed that Khanh Phuong Morrow, a Board Member at Lantheus Holdings (NASDAQ: LNTH), exercised stock options leading to a transaction valued at $0. This decision sheds light on the ongoing activities within the company and showcases the actions of key insiders....

Continue Reading
Investors Urged to Stay Informed on Organon & Co. Class Action

Updated Category News Views 170

Class Action Lawsuit Against Organon & Co. Pomerantz LLP has announced the initiation of a class action lawsuit against Organon & Co. This lawsuit primarily targets investors who have suffered losses relating to their investment in Organon (NYSE: OGN). With the launch of this lawsuit, it is essential for affected investors to understand their rights and options available...

Continue Reading
Sionna Therapeutics Faces Legal Scrutiny Amid Stock Plunge

Updated Category News Views 90

Stock Drop Sparks Legal Action August 10, 2026, wasn't exactly a banner day for Sionna Therapeutics' investors. We're talking about watching a stock nosedive by a jaw-dropping 92%, which is the kind of number that'd knock your socks off under normal circumstances. The catalyst? Some dismal results from the company's Phase 2a proof-of-concept study of SION-719 aimed at...

Continue Reading
Toll Brothers Unveils Stunning New Homes in Chapel Oaks

Updated Category News Views 221

Exciting New Model Homes at Chapel Oaks Community CHAPEL HILL, N.C. – Toll Brothers, Inc. (NYSE: TOL), a prominent name in luxury home construction, has recently announced the opening of their latest model home at the Chapel Oaks community. This new community marks a significant addition to their portfolio in the Raleigh area, providing prospective homeowners with...

Continue Reading